PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
May 1, 2008, 00:00
10.1016/S1098-3015(10)70785-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)70785-3/fulltext
Title :
PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70785-3&doi=10.1016/S1098-3015(10)70785-3
First page :
Section Title :
Open access? :
No
Section Order :
531